Aktienanalyse zu Arcutis Biotherapeutics, Inc. (ARQT)ARQTArcutis Biotherapeutics, Inc.

Arcutis Biotherapeutics, Inc. is a commercial-stage medical dermatology company. The Company develops therapies against biologically validated targets and produces a pipeline for a range of inflammatory dermatological conditions. Its portfolio consists of topical and systemic treatments to treat immune-mediated dermatological diseases and conditions. Its product portfolio includes ZORYVE Roflumilast Cream, ZORYVE Roflumilast Foam, and ARQ-234. The ZORYVE Roflumilast Cream is used for the treatment of seborrheic dermatitis in individuals aged 9 years and older. The ZORYVE Roflumilast Foam for the topical treatment of mild to moderate atopic dermatitis in adults and pediatric patients 6 years of age and older. The ARQ-234 is a fusion protein that is a checkpoint agonist of the CD200 Receptor (CD200R). CD200R is an immune-regulatory receptor which is an immunological checkpoint with a role in the maintenance of immune tolerance. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Arcutis Biotherapeutics appears to be a good buy right now due to its recent profit growth and strong revenue increase. The current price is $26.58, and the company reported a profit of $15.01 million for Q2 2026, a significant turnaround from a loss of $15.89 million last year. Additionally, the gross margin stands at an impressive 91.58%, indicating strong profitability. However, the main risk is the insider selling, which has increased by 106.52% over the last month, suggesting potential concerns among insiders about the stock's future performance.